Skip to main content
OpenTrials
Completed

NCT Number: NCT01331590

Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia

The purpose of this study is to determine the ability of G-CSF to disrupt the bone marrow microenvironment as a means to increase the efficacy of chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of Chicago Medical Center, Chicago, Illinois, United States

Loading trial locations.

About this study

In this study, we will combine G-CSF as priming prior to and during the administration of salvage chemotherapy regimen in ALL. Abundant data suggests that leukemic cells receive key growth and survival signals from the bone marrow microenvironment. Our preclinical data show that 4-5 days of G-CSF treatment is associated with a loss of osteoblasts and decreases expression of key chemokine/ cytokines which support lymphocyte development. The investigators hypothesize that G-CSF will disrupt the protective effects of the bone marrow microenvironment and augment the effect of chemotherapy in adults with ALL. This is a pilot study of G-CSF priming in adult patients with relapsed or refractory ALL to determine the feasibility and to characterize the effect of G-CSF treatment on the marrow microenvironment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Acute lymphoblastic leukemia diagnosed according to WHO criteria (>25% lymphoblasts in BM) which is relapsed or refractory to therapy. Patients with t(9;22) must be refractory to BCR-ABL tyrosine kinase inhibitors.
  • Age ≥ 18 years
  • ECOG performance status ≤ 3.
  • Adequate organ function defined as:
  • Calculated creatinine clearance ≥ 50 ml/min
  • AST, ALT, total bilirubin ≤ 2 x institutional ULN except when in the opinion of treating physician elevated levels are due to direct involvement of leukemia (eg. hepatic infiltration or biliary obstruction due to leukemia)
  • Women of childbearing potential and sexually active males must be willing and able to use effective contraception while on study.
  • Able to provide signed informed consent prior to registration on study.

Exclusion criteria

  • Previous salvage chemotherapy with ifosfamide and etoposide
  • Pregnant or nursing
  • Received any other investigational agent or cytotoxic chemotherapy within the preceding 2 weeks
  • Received colony stimulating factors filgrastim or sargramostim within 1 week or pegfilgrastim within 2 weeks of study
  • Severe concurrent illness that would limit compliance with study requirements

Treatment and study plan

G-CSF

Drug

Other names: Filgrastim, Neupogen, Granulocyte Colony-Stimulating Factor, Recombinant Methionyl Human G-CSF

ifosfamide

Drug

Other names: Ifex, Isophosphamide

etoposide

Drug

Other names: Etopophos, VP-16

Dexamethasone

Drug

Other names: Decadron

Mesna

Drug

Other names: Mesnex

Primary outcomes

  1. Treatment-related mortality

    Time frame: 30 days after start of treatment

  2. Delayed hematologic recovery

    Time frame: Day 46 of treatment

    Defined as neutrophil recovery (ANC > 1,000/mm3) > 42 days after the start of chemotherapy in the absence of persistent leukemia

Secondary outcomes

  1. Complete remission rate cytogenetic complete remission

    Time frame: 42 days

  2. Overall survival

    Time frame: 2 years

    Every 6 months

  3. Disease-free survival

    Time frame: 2 years

    Every 6 months

  4. Remission duration

    Time frame: 2 years

    Every 6 months

  5. Frequency and severity of adverse events

    Time frame: 30 days post treatment

  6. Interaction of pretreatment disease and patient characteristics on clinical outcomes

    Time frame: Baseline

    Morphology, cytogenetics, immunophenotype, WBC, and performance status

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Registry information

Official study title

A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukemia

Important dates

Study start
2011
Primary completion
2014
Study completion
2015
First posted
Apr 8, 2011
Registry last updated
Sep 20, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.